40,557 results on '"Metastatic breast cancer"'
Search Results
52. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
53. AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. (AURORA)
54. Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT)
55. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
56. Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 (ESME-MBC)
57. Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer
58. NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (TONIC-3)
59. Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (PATRICIA II)
60. HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 (HERMIA)
61. BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
62. Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression (TATEN)
63. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)
64. Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
65. Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP)
66. A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)
67. A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1)
68. Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy (DIAMOND)
69. A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
70. Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
71. Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT)
72. Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
73. The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity
74. Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
75. A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC)
76. A Qualitative Study on Treatment Adherence in Patients With Metastatic Breast Cancer
77. A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer
78. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
79. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
80. Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. (Palbociclib)
81. European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (EUCHARIS)
82. A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
83. HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
84. Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
85. Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
86. Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer
87. Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
88. Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone (RESPECT-MI)
89. Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer (CCR4-NOT)
90. A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES)
91. ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC) (ACT-MBC)
92. ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
93. A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07)
94. A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
95. Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
96. Estradiol Plus Olaparib for Breast Cancer (PHOEBE) (PHOEBE)
97. A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
98. Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer (TEP-FES)
99. A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
100. Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.